SenzaGen AB (OSTO:SENZA) ROCE % : -9.67% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is SenzaGen AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SenzaGen AB's annualized ROCE % for the quarter that ended in Dec. 2024 was -9.67%.

SenzaGen AB ROCE % Historical Data

The historical data trend for SenzaGen AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SenzaGen AB ROCE % Chart

SenzaGen AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-22.05

-28.66

-24.69

-27.12

-21.32

SenzaGen AB Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-16.40	-14.85	-35.10	-13.14	-9.67

SenzaGen AB ROCE % Calculation

SenzaGen AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-17.884	/	( ( (97.176 - 27.895)	+	(111.906 - 13.391) )	/ 2 )
	=	-17.884	/	( (69.281	+	98.515)	/ 2 )
	=	-17.884	/	83.898
	=	-21.32 %

SenzaGen AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-9.592	/	( ( (109.175 - 9.371)	+	(111.906 - 13.391) )	/ 2 )
	=	-9.592	/	( ( 99.804	+	98.515 )	/ 2 )
	=	-9.592	/	99.1595
	=	-9.67 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

SenzaGen AB (OSTO:SENZA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SenzaGen AB ROCE % Related Terms

Thank you for viewing the detailed overview of SenzaGen AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SenzaGen AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SenzaGen AB (OSTO:SENZA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Scheeletorget 1, Medicon Village, Building 401, Lund, SWE, 223 81

Website

https://www.senzagen.com

SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.

SenzaGen AB Headlines

No Headlines